Samsung Biologics will be participating in INTERPHEX Week Tokyo from July 9 to 11. The company will showcase its end-to end development and manufacturing services at booth #E12-60.
With expanded capabilities across diverse modalities including multispecifics, antibody-drug conjugates (ADCs), and mRNA along with the recent launch of its research services, Samsung Organoids, the company will highlight how its tailored approach and operational excellence can support clients advance their programs from start to finish with greater flexibility and efficiency.
A featured presentation will take place on July 9 at 15:50 JST at Bio Pharma EXPO Exhibitors’ Presentation Venue 9 (East Hall 7). Marc Studer, Senior Director and Head of ADC and mRNA Operations, will discuss key considerations in ADC drug substance manufacturing, including payload handling and cross-contamination control, demonstrating how specialized expertise and integrated solutions contribute to reliable program execution.
Samsung Biologics will be participating in INTERPHEX Week Tokyo from July 9 to 11. The company will showcase its end-to end development and manufacturing services at booth #E12-60.
With expanded capabilities across diverse modalities including multispecifics, antibody-drug conjugates (ADCs), and mRNA along with the recent launch of its research services, Samsung Organoids, the company will highlight how its tailored approach and operational excellence can support clients advance their programs from start to finish with greater flexibility and efficiency.
A featured presentation will take place on July 9 at 15:50 JST at Bio Pharma EXPO Exhibitors’ Presentation Venue 9 (East Hall 7). Marc Studer, Senior Director and Head of ADC and mRNA Operations, will discuss key considerations in ADC drug substance manufacturing, including payload handling and cross-contamination control, demonstrating how specialized expertise and integrated solutions contribute to reliable program execution.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article